Armistice Capital’s Travere Therapeutics TVTX Stock Holding History

Armistice Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$146M	Buy	4,897,417 +1,133,526	+30%	+$33.9M	2.59%	3
2025 Q4	$144M	Sell	3,763,891 -2,960,109	-44%	-$96.3M	1.71%	6
2025 Q3	$161M	Sell	6,724,000 -2,152,000	-24%	-$40.5M	2.38%	4
2025 Q2	$131M	Buy	8,876,000 +4,000	+0%	+$66.3K	2.27%	5
2025 Q1	$159M	Buy	8,872,000 +1,514,000	+21%	+$30.7M	2.38%	5
2024 Q4	$128M	Sell	7,358,000 -290,000	-4%	-$5.13M	1.75%	5
2024 Q3	$107M	Buy	7,648,000 +148,000	+2%	+$1.54M	1.71%	7
2024 Q2	$61.6M	Hold	7,500,000	–	–	0.78%	16
2024 Q1	$57.8M	Buy	7,500,000 +116,000	+2%	+$979K	0.77%	15
2023 Q4	$66.4M	Sell	7,384,000 -116,000	-2%	-$845K	0.91%	18
2023 Q3	$67M	Buy	7,500,000 +50,000	+0.7%	+$706K	1.03%	11
2023 Q2	$114M	Buy	7,450,000 +302,000	+4%	+$5.49M	1.66%	7
2023 Q1	$161M	Buy	7,148,000 +736,000	+11%	+$15.6M	2.31%	4
2022 Q4	$135M	Buy	6,412,000 +576,000	+10%	+$12.2M	2.35%	5
2022 Q3	$144M	Buy	5,836,000 +516,000	+10%	+$13.3M	2.49%	6
2022 Q2	$129K	Buy	5,320,000 +362,000	+7%	+$9.1M	2.25%	8
2022 Q1	$128M	Buy	4,958,000 +880,000	+22%	+$23.4M	2.47%	3
2021 Q4	$127M	Sell	4,078,000 -670,000	-14%	-$18.9M	2.07%	5
2021 Q3	$115M	Sell	4,748,000 -1,000,000	-17%	-$18.4M	1.95%	7
2021 Q2	$83.9M	Buy	5,748,000 +3,392,000	+144%	+$66.9M	1.5%	15
2021 Q1	$58.8M	Buy	+2,356,000	New	+$65.1M	1.35%	19
2015 Q1	–	Sell	-34,874	Closed	-$427K	–	29
2014 Q4	$427K	Buy	+34,874	New	+$361K	0.21%	29

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Armistice Capital's TVTX Position: Q1 2026 in Review

Armistice Capital increased its Travere Therapeutics (TVTX) stake by 30% in Q1 2026, buying an estimated $33.9M and bringing the position to 4,897,417 shares worth $146M. The position accounts for 2.59% of the portfolio, ranked #3.

Armistice Capital first reported a position in TVTX in Q4 2014 and has held it in 22 quarters since. The position peaked at $161M in Q1 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Armistice Capital held 4,897,417 shares of Travere Therapeutics worth $146M as of Q1 2026.
Armistice Capital bought 1,133,526 Travere Therapeutics shares in Q1 2026, an estimated $33.9M.
Travere Therapeutics made up 2.59% of Armistice Capital's portfolio in Q1 2026, its #3 holding.
Armistice Capital first reported a position in Travere Therapeutics in Q4 2014 and has held it in 22 quarters since.
Armistice Capital's Travere Therapeutics position peaked at $161M in Q1 2023.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.